Repurposing of PI3K inhibitors for high-grade serous ovarian cancer: A novel competing endogenous network analysis-based approach
Anna Erol, Karolina Chwiałkowska, Anna Zeller, Anna Skwarska et autres
INTRODUCTION: The average survival time for High-Grade Serous Ovarian Cancer (HGSOC) is around 3.4 years post-diagnosis. The treatment options are limited, especially for relapsed patients, resistant to standard treatment. Therefore, novel drug candidates are needed. OBJECTIVE: We propose a novel approach for …
pl, us (code pays fourni par la source)
3 citations
Computers in Biology and Medicine